If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to end October, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SMCI over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am no ...

NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) between December 15, 2021 and September 16, 2025, both dates inclusive (the “Class Period”), of the important November 20, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased RCI Hospitality securities during the Class Period you may be entitled to compensation without ...

Analyst’s Disclosure:I/we have a beneficial long position in the shares of RIET, HOMZ, IRET, ALL HOLDINGS IN THE IREIT+HOYA PORTFOLIOS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Hoya Capital Research & Index Innovations ("Hoya Capital") is an affiliate of Hoya Capit ...

SSR Mining (NASDAQ: SSRM ) is one of the few interesting mid-cap miners there are in the market. It has diversified mining portfolio in North and South America and Turkey as well. Why is it interesting to me? MightI’m an independent equity trader and licensed financial advisor focused on uncovering high-upside opportunities in overlooked sectors — especially small-caps, energy, commodities, and special situations. My investment strategy is rooted in the CAN SLIM framework but goes further. I look for fundam ...

I am a value-oriented investor who seeks out high-quality companies with long histories of dividend growth. I believe that patient investors who build a core portfolio of dividend paying equities can achieve their retirement goals without taking on unnecessary risk. Dividend growth profiles are the best indicators of management's commitment to returning cash to shareholders. Dividend growth investing involves identifying quality companies with competitive advantages that provide visibility towards future ca ...

Core Insights - The article emphasizes the importance of dividend growth stocks for long-term wealth building, highlighting three specific stocks that combine growth potential with increasing dividend income [2][3]. Group 1: Johnson & Johnson (NYSE: JNJ) - JNJ has raised dividends for 63 consecutive years, showcasing resilience and reliable income [7]. - The company operates in three segments: pharmaceuticals (45% of revenue), medical devices, and consumer health, providing diversification against cyclical risks [8]. - In Q3 2025, JNJ reported a revenue growth of 6.8% year-over-year to $24 billion, with earnings per share rising 15.7% to $2.80, driven by new drug approvals and innovation [9]. - JNJ holds a AAA credit rating, indicating strong financial health, with a payout ratio near 50%, allowing for dividend growth [10]. - The annual dividend is $5.20 per share, with a yield of approximately 3.05% and a recent increase of 4.8% [12]. Group 2: Procter & Gamble (NYSE: PG) - PG has a record of 69 consecutive years of dividend increases, reflecting strong management and commitment to shareholder value [16]. - The company’s diverse portfolio includes brands in fabric care, baby care, grooming, oral care, and personal health, which helps cushion earnings during economic cycles [17]. - In fiscal 2025, PG achieved 2% organic sales growth and 4% core earnings per share growth, aided by innovation and supply chain improvements [18]. - PG maintains a payout ratio of around 62%, with a dividend yield of approximately 2.5% and consistent annual hikes of 5-6% [19]. Group 3: Realty Income Corporation (NYSE: O) - Realty Income is known for 664 consecutive monthly dividends and over 30 years of dividend growth, providing predictable income [24]. - The REIT focuses on retail and commercial properties under triple-net leases, ensuring steady demand from tenants [25]. - Recent quarterly earnings showed a 5% increase in funds from operations, supported by strategic acquisitions and rent escalations [26]. - Realty Income's dividend yield is around 4.5%, backed by consistent FFO growth [28]. Group 4: Investment Strategy and Mindset - The article advocates for a long-term investment mindset, emphasizing the importance of patience and the compounding effect of reinvesting dividends [33][35]. - It suggests a three-step research process for building a dividend growth portfolio, focusing on dividend history, financial health, and competitive advantages [35].

Core Insights - Concerns are rising about the potential for a bubble in AI stocks, reminiscent of the dot-com era, despite significant profits being reported by these companies [1][2] Group 1: Market Performance and Valuations - AI stocks have seen substantial increases in value, leading to debates about whether they are overpriced [1] - The Vanguard High Dividend Yield ETF outperformed the S&P 500 during the 2022 market crash, declining only 3% compared to the S&P 500's 19% drop [8] - The Vanguard U.S. Minimum Volatility ETF also performed better than the S&P 500, with a decline of nearly 8% during the same period [11] Group 2: Investment Options - The Vanguard High Dividend Yield ETF focuses on high-yielding stocks, providing diversification with a portfolio of 566 stocks, including blue-chip companies like Procter & Gamble and Walmart [5][6] - This ETF offers a dividend yield of around 2.5%, significantly higher than the S&P 500's average of 1.2%, with a low expense ratio of 0.06% [8] - The Vanguard U.S. Minimum Volatility ETF invests in low-volatility stocks, with 188 holdings and no single stock accounting for more than 2% of the portfolio, featuring companies like Coca-Cola and Cisco Systems [10][12]

In March 2025 , I rated Six Flags Entertainment Corporation (NYSE: FUN ) as a "wait-and-see hold", because although the top line had increased a lot from its merger with Cedar Fair , there were many concernsI am a freelancer with a business education who loves to discover new ideas for long and short term investments."Stop hoping for a promotion that's not coming. Instead, start a business at which you want to work." Sallie KrawcheckAnalyst’s Disclosure:I/we have no stock, option or similar derivative posit ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences over traditional monoclonal antibody treatments [4]. Allegations and Discrepancies - The lawsuit alleges that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company providing managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was able to mitigate negative effects of healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2% to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding full-year adjusted earnings expectations of no less than $19.00 per diluted share, Molina's stock price fell by $32.03, or 16.8%, from $190.25 to $158.22 per share [4].